Critical Contrast: Agenus (NASDAQ:AGEN) versus Scinai Immunotherapeutics (NASDAQ:SCNI)

Agenus (NASDAQ:AGEN) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Earnings and Valuation

This table compares Agenus and Scinai Immunotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$132.69 million	2.55	$120,000.00	$2.58	2.92
Scinai Immunotherapeutics	$1.31 million	0.93	-$8.31 million	($1.06)	-0.22

Agenus has higher revenue and earnings than Scinai Immunotherapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Agenus and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Scinai Immunotherapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations for Agenus and Scinai Immunotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1	1	2	0	2.25
Scinai Immunotherapeutics	1	0	0	0	1.00

Agenus currently has a consensus price target of $19.50, suggesting a potential upside of 158.96%. Given Agenus’ stronger consensus rating and higher probable upside, analysts clearly believe Agenus is more favorable than Scinai Immunotherapeutics.

Insider & Institutional Ownership

61.5% of Agenus shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Agenus has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500.

Summary

Agenus beats Scinai Immunotherapeutics on 12 of the 14 factors compared between the two stocks.

About Agenus

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.